Loading clinical trials...
Loading clinical trials...
Open, Single Arm,Multicenter Phase 2 Clinical Study to Evaluating the Efficacy and Safety of the Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T) for CD19 Positive Lymphoma
Conditions
Interventions
The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)
Locations
1
China
Jiangsu Cancer hospital
Nanjing, Jiangsu, China
Start Date
April 1, 2017
Primary Completion Date
March 1, 2021
Completion Date
March 1, 2021
Last Updated
March 22, 2017
NCT06263491
NCT07388563
NCT06337318
NCT05139017
NCT05529069
NCT06189391
Lead Sponsor
Sinobioway Cell Therapy Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions